Arcturus Therapeutics to Present at Three Investor Conferences in September

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/23/2026

1. WMT
2. ROST
3. AAP
4. NVDA
5. SPY

6. BABA
7. AVGO
8. SPCX
9. BJ
10. DE

Get Alerts ARCT Hot Sheet

Price: $13.45 +22.38%

Overall Analyst Rating:
SELL (= Flat)

Dividend Yield: 6%

Join SI Premium – FREE

SAN DIEGO, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, today announced that Joseph E. Payne will present at the upcoming conferences, including the B. Riley FBR Annual Healthcare Conference, the H.C. Wainwright & Co. 20th Annual Investor Conference, and the BioCentury 25th Annual NewsMakers in the Biotech Industry.

B. Riley FBR Annual Healthcare Conference
Presenter:	Joseph Payne, President & CEO
Date:	Tuesday, September 4
Time:	8:20 AM – 9:20 AM
Location:	New York Marriott East Side, New York City

H.C. Wainwright 20th Annual Global Investment Conference
Presenter:	Joseph Payne, President & CEO
Date:	Thursday, September 6
Time:	4:40 PM – 5:05 PM
Location:	St. Regis Hotel, New York City

BioCentury 25th Annual NewsMakers in the Biotech Industry
Presenter:	Joseph Payne, President & CEO
Date:	Friday, September 7
Time:	10:00 AM – 10:25 AM
Location:	Millennium Broadway Hotel & Conference Center, New York City

About Arcturus Therapeutics Ltd.Founded in 2013 and based in San Diego, Arcturus Therapeutics Ltd. (NASDAQ: ARCT) is an RNA medicines company with enabling technologies – UNA Oligomer chemistry and LUNAR® lipid-mediated delivery. Arcturus’ diverse pipeline of RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis, and vaccines. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA and gene editing therapeutics. Arcturus owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology including UNA Oligomers, which are covered by its extensive patent portfolio (140 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ proprietary UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. Arcturus’ commitment to the development of novel RNA therapeutics has led to partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG and Cystic Fibrosis Foundation Therapeutics Inc. For more information, visit www.Arcturusrx.com, the content of which is not incorporated herein by reference.

Arcturus Contact

Neda SafarzadehArcturus Therapeutics(858) 900-2682[email protected]

Arcturus Investor ContactMichael WoodLifeSci Advisors LLC(646) 597-6983[email protected]